A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03

Inclusion Criteria:

• Participants are eligible to be included in the study only if all the followingcriteria apply:
• Participant met all inclusion/exclusion criteria of either Protocol RLM-MD-01 (NCT03285308) or Protocol RLM-MD-02 (NCT03426345) and successfully completed the study
• Able to provide written informed consent (IC) prior to any study procedures andwilling and able to comply with study procedures
• In the opinion of the investigator, the participant demonstrated adequate compliancewith the study procedures in Study RLM-MD-01 or RLM-MD-02

Exclusion Criteria:

• Participants are excluded from the study if any of the following criteria apply:
• Participant is not willing or able to abide by the restrictions regarding concomitantmedicine use
• Participant is planning to receive an investigational drug (other than studytreatment) or investigational device at any time during Study RLM-MD-03
• Participant has an unresolved adverse event (AE) or a clinically significant findingon physical examination, clinical laboratory test, or 12-lead electrocardiogram (ECG)that, in the investigator's opinion, would limit the participant's ability toparticipate in or complete the study
• Any other reason that, in the investigator's opinion, would confound properinterpretation of the study or expose a participant to unacceptable risk, includingrenal, hepatic or cardiopulmonary disease